Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 2Active not recruiting 2Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 44Precursor Cell Lymphoblastic Leukemia-Lymphoma 30Myelodysplastic Syndromes 26Lymphoma, Non-Hodgkin 20Hematologic Neoplasms 20Lymphoma 19Multiple Myeloma 18Lymphoma, B-Cell 15Recurrence 14Lymphoma, Large B-Cell, Diffuse 13Leukemia, Lymphocytic, Chronic, B-Cell 12Burkitt Lymphoma 12Breast Neoplasms 11Pancreatic Neoplasms 10Lymphoma, Follicular 10Ovarian Neoplasms 9Melanoma 9Leukemia, Myelomonocytic, Chronic 9Neoplasm Metastasis 8Myeloproliferative Disorders 8Stomach Neoplasms 7Lymphoma, Mantle-Cell 7Lymphoma, B-Cell, Marginal Zone 7Leukemia, Biphenotypic, Acute 7Leukemia 7Hodgkin Disease 7Glioblastoma 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Triple Negative Breast Neoplasms 6

Interventions

atezolizumab 3fludarabine 2entrectinib 2cobimetinib 2capmatinib 2alectinib 2Vemurafenib 2Pemetrexed 2Nivolumab 2Cisplatin 2spartalizumab 1repotrectinib 1pertuzumab 1lutetium Lu 177 dotatate 1gilteritinib 1enzalutamide 1durvalumab 1copper dotatate CU-64 1cemiplimab 1Trastuzumab 1Sodium Chloride 1Radiotherapy 1Radiosurgery 1Mitomycin 1Lutetium-177 1Lutetium 1Injections 1Idarubicin 1HuMax-IL8 1Granulocyte Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Neoplasms by Histologic Type × fludarabine × Clear all
NCT06001788 2026-04-14

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Kura Oncology, Inc.

Phase 1 Recruiting
171 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT05963217 2025-07-02

Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

University Health Network, Toronto

Phase 1 Recruiting
19 enrolled
LymphoidOther hematologic neoplasm

Immune System Diseases, Lymphoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Experimental, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡